Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Palvella Therapeutics (Nasdaq: PVLA) will report its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. Management will host an investor conference call and webcast at 8:30 a.m. ET that day, with online and phone access plus a 90-day replay.
Details
News Market Reaction – PVLA
On Jul 28, the day this news came out, PVLA closed 0.75% above the previous close.
Data tracked by StockTitan Argus for the Jul 28 session.
Key Figures
- Reporting period
- Second quarter 2026
- Financial results
- Results date
- August 4, 2026
- Before market open
- Conference call time
- 8:30 a.m. ET
- August 4, 2026
- Replay availability
- Approximately two hours
- After the call concludes
- Replay archive
- 90 days
- Company website archive
Previous Conferences,earnings date Reports
-
Scheduled first-quarter 2026 results and corporate update call
-
Scheduled full-year 2025 results and corporate update call
-
Scheduled third-quarter 2025 results and corporate update call
-
Scheduled second-quarter 2025 results conference call
-
Scheduled first-quarter 2025 results and corporate update call
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that it will report its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update.
To access the live webcast, including presentation slides, please click here or visit the “Events & Presentations” section of Palvella’s website. To access the conference call by phone, register using this link, and you will be provided with dial-in details. A replay of the webcast will be available approximately two hours after the conclusion of the call and will remain archived for 90 days under the “Events & Presentations” section of the Company's website at www.palvellatx.com.
About Palvella Therapeutics
Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients living with serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular malformations, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™
QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.
Contact Information
Investors
Wesley H. Kaupinen
Founder and Chief Executive Officer
Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Vice President of Investor Relations and Corporate Affairs
Palvella Therapeutics
marcy.nanus@palvellatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.